info@seagull-health.com
SeagullHealth
search
Alkeran(Melphalan)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Alkeran(Melphalan) Instructions:Uses,Dosage, Side Effects
Melphalan, marketed under the brand name ALKERAN, is an alkylating chemotherapeutic agent primarily used in the treatment of multiple myeloma and non-resectable epithelial carcinoma of the ovary. It exerts its therapeutic effect by inducing DNA cross-linking, which leads to cell damage, particularly in rapidly dividing tumor cells. Since its introduction in 1953, it has become a cornerstone in treating hematologic cancers, especially when other treatments fail.
Due to its potential for severe side effects, such as bone marrow suppression and leukopenia, ALKERAN should only be administered under the supervision of a physician experienced in cancer therapies. Regular monitoring of blood counts is essential to avoid complications associated with prolonged use.
Palliative treatment of multiple myeloma;Palliative treatment of non-resectable epithelial carcinoma of the ovary.
The dosage of ALKERAN should be carefully tailored to the patient's condition, with close monitoring of blood counts. The drug is administered orally in the form of tablets. Blood tests, including platelet count, hemoglobin levels, and white blood cell count, must be regularly performed to assess bone marrow suppression. The exact dosage depends on the specific condition being treated and patient response to therapy.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
